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We report a case of Yersinia enterocolitica septicemia in a 63-year-old patient admitted
to the Vascular Surgery Department of Umberto I Hospital (Rome, Italy) for an abdominal
aortic aneurysm. The microorganism, recovered from both peripheral blood cultures
and aneurysmatic aortic wall specimens, was identified as Y. enterocolitica using
matrix-assisted laser desorption ionization–time of flight analysis (MALDI-TOF MS) and
16S rDNA gene sequencing. The isolate responsible for septicemia belonged to the O:9
serotype (biogroup 2). A genetic screening of the isolate made it possible to detect
the presence of both the yst and ail genes, encoding a heat-stable enterotoxin and
a protein involved in invasion/adherence and serum resistance, respectively. Our case
contributes in enriching epidemiological data concerning Y. enterocolitica infections,
which might represent severe complications in patients suffering from cardiovascular
diseases. Moreover, this study, together with the others, should be regarded as valuable
and useful tools for monitoring the rate of infections worldwide.
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INTRODUCTION
Yersinia enterocolitica is a non-spore Gram-negative bacterium belonging to Yersinia genus and
to the Enterobacteriaceae family. Among Yersinia species, only Y. pestis, Y. pseudotuberculosis,
and some Y. enterocolitica strains are pathogenic for humans, whereas others are environmental
species that might be opportunistic pathogens. Y. enterocolitica is a heterogeneous group of
bacterial strains, classified into 6 biogroups (1A, 1B, 2, 3, 4, and 5) based on phenotypic
characteristics, human/animal pathogenicity, and ecologic and geographic distribution (1).
Serologically, Y. enterocolitica is further distinguished into more than 57 O serogroups, depending
on their lipopolysaccharide-O-antigens. Only isolates belonging to biogroup 1Amay be considered
avirulent so far. Among the other 5 biogroups, strains belonging to serogroups O:3 (biogroup 4),
O:5,27 (biogroups 2 and 3), O:8 (biogroup 1B), and O:9 (biogroup 2) are most commonly isolated
from human samples worldwide (2, 3). However, the most prevalent Y. enterocolitica serogroup in
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many European countries is serogroup O:3 followed by O:9,
whereas the serogroupO:8 is mainly detected in the United States
(1, 3). Despite a significant decrease between 2008 and 2016,
human Yersiniosis represents the third most commonly reported
bacterial food-borne zoonosis in all EU countries (https://ecdc.
europa.eu/).
As a foodborne pathogen, Y. enterocolitica causes acute
terminal ileitis and mesenteric Iymphadenitis. Depending on
both patient conditions and bacterial serogroup, it can spread
at the systemic level (3, 4). Several septic complications have
been described that can evolve, eventually, into endocarditis
or infected aortic aneurysm, also known as mycotic aneurysm
(3). At present, only 14 papers associated with Y. enterocolitica
have been reported in literature (Table 1), including 13 cases
of infected abdominal aortic aneurysms (AAA). The main
pathogenic properties of Y. enterocolitica are due to the presence
TABLE 1 | Data summarizing previously reported cases of Y. enterocolitica mycotic aneurysms.
References Age Sex First isolated
from
GI
symptoms
Endocarditis Site of
aneurysm
Serogroup/
Biogroup
Antibiotic
therapy
Outcome
(5) 53 M Stool and blood Yes No Carotid artery Biotype 4 Cefamandole Good
(6) 79 M Blood Yes No AAA* Serotype O:3,
Biotype 4
Ampicillin and
gentamicin
Fatal
(7) 76 M Aneurysm wall Yes No AAA* Serotype O:9,
Biotype 2
Gentamicin
and Co-
trimoxazole
Good
(8) 59 M Blood Yes No AAA* Biotype 4 Cefuroxime
and
metronidazole
Fatal
(9) (6 cases) 73 M Blood No No AAA* and
Popliteal
Artery
Serotype O:9 Ciprofloxcin
and Co-
trimoxazole
Fatal (2/6)
(10) 57 M Resected aorta No No AAA* Serotype O:3,
Biotype 4
Ciprofloxacin
and
aztreonam
Fatal
(11) (3 cases) 70 M Blood No No AAA* Serotype O:9 Ciprofloxcin
/tetracycline
and
Ceftriaxone
Fatal (2/3)
(12) 64 M Blood Yes No Femoral
artery and
AAA*
Unspecified Unspecified Fatal
(13) 78 M Blood No No AAA* Serotype O:9,
Biotype 2
Ofloxacin Good
(14) 55 M Blood No No AAA* Serotype O:3,
Biotype 4
Gentamicin
and
ceftriaxone
Fatal
(15) 70 M Vascular graft No No AAA* Serotype O:3,
Biotype 4
Cefotaxime
and
ciprofloxacin
Good
(16) 74 M Blood Yes Yes AAA* No
serogroup/Biotype
2
Amoxicillin,
metronidazole
and
gentamicin
Good
(17) 78 M Blood No Yes AAA* Unspecified Ciprofloxacin Good
(18) 68 M Blood No No AAA* Unspecified Piperacillin-
tazobactam
Good
*AAA, abdominal aortic aneurysms.
of the two chromosomally encoded genes, ail and yst (1, 19,
20). The ail gene encodes for the membrane-associated protein
Ail, involved in adhesion to and invasion into eukaryotic
cells, as well as serum resistance. Conversely, the yst gene
encodes for thermostable enterotoxin Yst, whose presence is
related with diarrheal illness, although its role remains largely
controversial (21). Being the most common virulence genes of
Y. enterocolitica, both are considered excellent PCR targets for
bacterial detection and subtyping as well as for its pathogenicity
potential (22).
Herein, we describe a case of Y. enterocolitica
septicemia in a patient suffering from an AAA
Microbiological and molecular analyses have demonstrated
the presence of a strain belonging to the O:9 serotype,
carrying both the ail and yst genes and resistant to
amoxicillin/clavulanate.
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CASE REPORT
Ethics Statement
The subject gave a written informed consent in accordance with
the Declaration of Helsinki.
A 63-year-old patient was admitted to the Vascular Surgery
Department of Umberto I Hospital (Rome, Italy) for an AAA.
At admission, the patient presented with low-grade fever
(37.2◦C) and reported a history of asthenia and weight loss in
the previous months. No abdominal symptoms, vomiting or
diarrhea were referred. In September 2017, the patient performed
an abdominal ultrasound and blood tests, including three sets
of peripheral blood culture that were sent to the Microbiology
laboratory. Blood tests showed an erythrocyte sedimentation
rate of 48 mm/h, a white blood cell (WBC) count of 13.94 ×
109/L and a C-reactive protein (CRP) level of 185 mg/L. An
empirical therapy was therefore started with the intravenous
administration of daptomycin (500mg die), ertapenem (1 g die),
and fluconazole (400mg die). Abdominal ultrasound identified
described an abdominal aortic aneurysm with a diameter of
6.42 cm. The computed tomography (CT) scan confirmed the
presence of the AAA with a periaortic inflammation (Figure 1).
Moreover, transthoracic echocardiogram ruled out active
endocarditis. The patient therefore underwent endovascular
repair. After 24 h of incubation in the automatic Virtuo
BacT/ALERT (bioMérieux, Inc. France), two sets of blood
cultures became positive. Microscopic examination revealed
motile Gram-negative coccobacilli. Colonies on MacConkey
agar were small, round and non-lactose fermenting. Colonies
were subcultured onto CIN agar plates (Cefsulodin Irgasan
Novobiocin) (bioMérieux, Inc. France), selective for Yersinia
spp. After 24 h of incubation at 28◦C, the colonies displayed
the typical red bull’s eye appearance, characterized by a red
center with a colorless translucent rim (Figure 2). Biochemical
tests of the colonies, using VITEK 2 System (bioMérieux,
Inc. France), identified Y. enterocolitica/frederiksenii with 99%
probability. Accordingly, MALDI-TOF MS System confirmed
the identification of Y. enterocolitica, with a score of 2.265
(23) (Figure 3). Finally, the 16S rDNA gene sequence analysis
confirmed the Y. enterocolitica identification. Antibiotic
susceptibility tests with VITEK 2 System (bioMérieux, Inc.
France) and MICROSCAN WalkAway System 96 Plus
(Beckman Coulter S.r.l.) revealed that the Y. enterocolitica
isolate was susceptible to all antibiotics tested, except to
amoxicillin/clavulanate (Table 2). Serogrouping analysis
using specific Y. enterocolitica antisera evidenced that the Y.
enterocolitica isolate belonged to the O:9 serotype (biogroup
2). Finally, the presence of both ail and yst genes in the Y.
enterocolitica isolate was detected using Real-time PCR.
Two weeks after the endovascular procedure, the patient
underwent open surgical repair. During the procedure, the
surgeon reported a strong foul necrotic smell and noticed
tight adhesions between the inflamed small intestine and the
aneurysm. Specimens were collected from the aneurysmatic
aortic wall and sent to the Microbiology laboratory. These
aneurysm specimens were, firstly, incubated in brain heart
infusion (BHI) broth and, subsequently, plated on different
FIGURE 1 | Preoperative CT scan showing an abdominal aortic
aneurysm surrounded by inflammation/fluid collection (white arrow).
microbiological media, including CIN agar plates. Again,
microbiological, biochemical, molecular, antibiotic susceptibility,
and serogrouping analyses identified the clinical isolate as
Y. enterocolitica O:9 serotype (biogroup 2). Therefore, we
concluded that the same Y. enterocolitica isolate was colonizing
the patient. The antibiotic therapy was modified; the patient
suspended daptomycin and fluconazole and was treated
intravenously with ertapenem (1 g die) and tigecycline (100mg
for first day and 50mg for following days) for 4 weeks. Over this
period, all the sets of blood culture were negative. The patient
was discharged home 8 weeks after surgery.
MATERIALS AND METHODS
Peripheral blood culture bottles, for both aerobic and anaerobic
microorganisms, were incubated for 24 h in the automatic Virtuo
BacT/ALERT (bioMérieux, Inc. France). Aneurysm specimens
were incubated in BHI at 37◦C for 24 h. Clinical isolates were
examined under light microscope (400x) for motility and upon
Gram staining. In parallel, isolates were seeded on Blood agar,
MacConkey agar, Extended Spectrum Beta-Lactamase (ESBL)
agar (bioMérieux, Inc. France), and CIN agar plates and
incubated at 28◦C for 24 h. Colonies were identified by VITEK
2 System (bioMérieux, Inc. France), by MALDI-TOF MS System
(Bruker Daltonics, Inc.) and by 16S rDNA gene sequencing, as
previously described respectively in Febbraro et al. (24) and in Yu
et al. (25). Antimicrobial susceptibility testing was performed by
VITEK 2 System (bioMérieux, Inc. France) and byMICROSCAN
WalkAway System 96 Plus (Beckman Coulter S.r.l.). The
resulting minimum inhibitory concentration (MIC) values were
classified into clinical categories of susceptible, intermediate
or resistant, following the EUCAST recommendations (26).
Serogrouping analysis was performed by slide agglutination
using O:3, O:5, O:8, and O:9 antisera (Biogenetics, s.r.l. Italy)
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FIGURE 2 | Y. enterocolitica on CIN agar: small colonies with the typical red
bull’s eye appearance, namely a red center with colorless translucent rim.
following the recommendation of the manufacturer. Real-
time PCR was performed as previously described (21). Both
analyses were carried out at the Experimental Zooprophylactic
Institute of Lazio and Tuscany “Mariano Aleandri” (Rome,
Italy).
DISCUSSION
There has been an increasing body of evidence showing that Y.
enterocolitica serogroups O:3 and O:9 are a cause of mycotic
aneurysm and septicaemia, mainly in males over 50 years, with
risk factors for cardiovascular disease (10, 14). Herein, we report
a case of Y. enterocolitica serogroup O:9 (biogroup 2) septicemia
in a patient with an AAA. It is important to note that this is the
first study reporting the identification of Y. enterocolitica both
in the peripheral blood and in the specimens collected from the
aneurysmatic aortic wall.
It has been reported that, following ingestion, virulent Y.
enterocolitica crosses the intestinal mucus layer and binds
to the M cells overlying Peyer’s Patches. Thereafter, bacteria
penetrate these cells to gain access to and multiply in subjacent
tissue. Among others, attachment and invasion of M cells is
promoted by the membrane-associated Ail protein, encoded
by the chromosomal invasion ail gene, thereby facilitating the
spread to several tissues, as well as bloodstream (1). Also in
this environment, Ail provides strong protection to complement
killing bactericidal activity, thereby allowing survival of bacteria
in the blood and increasing its spreading (1). Due to Y.
enterocolitica predilection for vascular tissues, it is highly likable
that bacteria colonize the aneurysmatic aorta during bacteremia.
On the other hand, the thermostable enterotoxin Yst, encoded
by the yst gene, is mainly related with diarrheal illness (21).
FIGURE 3 | Peptide mass fingerprinting of Y. enterocolitica from peripheral blood cultures (A) and from aneurysm specimens (B) by MALDI-TOF MS.
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TABLE 2 | Antibiotic susceptibility MICs (expressed as mg/L) of the Y.
enterocolitica isolate.
Antibiotic MIC VITEK2 MIC MICROSCAN EUCAST 2017
Amikacin 4 ≤8 S
Amoxicillin/Clavulanate 16 16 R
Cefepime ≤1 ≤1 S
Cefotaxime ≤1 ≤1 S
Ceftazidime ≤1 ≤1 S
Colistin ≤0.5* ≤2 S
Ciprofloxacin ≤0.25 ≤0.5 S
Ertapenem ≤0.5 ≤0.5 S
Fosfomycin ≤16 ≤32 S
Gentamicin ≤1 ≤2 S
Imipenem ≤0.25 ≤1 S
Meropenem ≤0.25 ≤1 S
Tigecycline ≤0.5 ≤1 S
*The result of Colistin obtained with the VITEK2 method has a high percentage of Very
Major Error as reported by the company.
Although its role remains largely controversial, it has been
reported in an animal model that Yst can cause weight loss
without the occurrence of diarrhea, possibly depending on the
degree of host immune competency.
Our clinical and microbiological data support the hypothesis
that Y. enterocolitica firstly colonized the patient’s intestine.
Accordingly, the patient referred a weight loss in the previous
months. Thereafter, the inflammatory process of the small
intestine, in tightly conjunction to the aneurysm, allowed
Y. enterocolitica translocation into the aneurysm, thereby
shortening the period of bacteraemia. Y. enterocolitica
septicemia occurs commonly in patients suffering from
underlying disease(s) (1). Although our patient did not seem
to have predisposing factors, the high degree of inflammation
of the small intestine might have even favored Y. enterocolitica
translocation into the aneurysm.
CONCLUDING REMARKS
Our case contributes in enriching epidemiological data
concerning Y. enterocolitica infections, which might represent
severe complications in patients suffering from cardiovascular
diseases. The most common site of infections in these patients is
the aortic aneurysm, causing the mycotic aneurysm. Therefore,
colonization of the aneurysmatic aorta during bacteraemia can
lead to vessel rupture due to inflammation and necrosis, but
also to endocarditis, due to the contiguity of the infection site
(1, 18). Finally, together with the previous reports, our case
underlines the importance of the microbiological surveillance
of Y. enterocolitica. Regretfully, no routine screening test for
detecting Y. enterocolitica for cardiovascular disease patients
is available at the moment. No reliable data of monitoring
circulating Yersinia spp. on food and animals are available,
since it is not mandatory for Zooprophylactic Institutes to
report data (27). Therefore, all case reports on Y. enterocolitica
involved in cardiovascular diseases should be regarded as
valuable and useful tools to monitor the rate of infections
worldwide.
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